The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis.

Rieke E AltenGerd R BurmesterMarco Matucci-CerinicJean-Hugues SalmonPedro Lopez-RomeroWalid FakhouriInmaculada de la TorreLiliana Zaremba-PechmannThorsten HolzkämperBruno Fautrel

Published in: Rheumatology and therapy (2022)

In real-world settings, patients with RA initiating treatment with baricitinib were older and had longer disease duration than those initiating treatment with any other tsDMARD or any bDMARD. Initial descriptive data regarding treatment discontinuation (including reasons for discontinuation), effectiveness, and treatment patterns will be enriched as the study progresses.

Keyphrases

rheumatoid arthritis
randomized controlled trial
physical activity
machine learning
drug delivery
combination therapy
systemic sclerosis
data analysis